<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00542880</url>
  </required_header>
  <id_info>
    <org_study_id>D5892C00016</org_study_id>
    <nct_id>NCT00542880</nct_id>
  </id_info>
  <brief_title>Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®</brief_title>
  <acronym>SPEED</acronym>
  <official_title>A Double-blind, Randomised, Cross-over, Multi-centre Study, to Evaluate Onset of Effect in the Morning in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort®Turbuhaler® 320/9 μg, Compared With Seretide® Diskus® 50/500 μg, Both Given as One Inhalation Twice Daily for One Week Each.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the effects with two different inhaled respiratory medications with
      regards to improvement of lung function, symptoms and morning activities.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Expiratory Flow (PEF) 5 Minutes After Morning Dose</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from baseline in PEF was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and all days of treatment, with baseline as covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PEF Before Morning Dose</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF 15 Minutes After Morning Dose</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF Before Evening Dose</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Before Morning Dose</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 15 Minutes After Morning Dose</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Before Evening Dose</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PEF From Before Dose to 5 Minutes After Dose in the Morning</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with pre-dose run-in/washout as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PEF From Before Dose to 15 Minutes After Dose in the Morning</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with mean pre-dose run-in/washout as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1from Before Dose to 5 Minutes After Dose in the Morning</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with mean pre-dose run-in/washout as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1 From Before Dose to 15 Minutes After Dose in the Morning</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with mean pre-dose run-in/washout as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1 From Before Dose to 5 Minutes After Dose at the Clinic</measure>
    <time_frame>Baseline (run-in, and washout) and day 1 of treatment period</time_frame>
    <description>The change from pre-dose was calculated using the pre-dose baseline value (run-in and washout period respectively), and pre-dose value at day 1, with pre-dose run-in/washout as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC) From Before Dose to5 Minutes After Dose at the Clinic</measure>
    <time_frame>Baseline (run-in, and washout) and day 1 of treatment period</time_frame>
    <description>The change from pre-dose was calculated using the pre-dose baseline value (run-in and washout period respectively), and pre-dose value at day 1, with pre-dose run-in/washout as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capacity of Daily Living in the Morning (CDLM) (Change From Pre to End of Treatment)</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate. Score scale 0 - 5 with 0=worst and 5 = best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty in Getting Out From Bed (MASQ) (Change From Pre to End of Treatment)</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate. Score scale 0 - 5 with 0=worst and 5 = best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Clinical Chronic Obstructive Pulmonary Disease (COPD) Questionnaire (Change From Pre to End of Treatment)</measure>
    <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
    <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate. Score scale 0 - 6 with 0=worst and 6 = best.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">442</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Symbicort Turbuhaler First, then Seretide Diskus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg First, then Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seretide Diskus First, then Symbicort Turbuhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg First, then Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</intervention_name>
    <arm_group_label>Symbicort Turbuhaler First, then Seretide Diskus</arm_group_label>
    <arm_group_label>Seretide Diskus First, then Symbicort Turbuhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</intervention_name>
    <arm_group_label>Symbicort Turbuhaler First, then Seretide Diskus</arm_group_label>
    <arm_group_label>Seretide Diskus First, then Symbicort Turbuhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient, female or male aged ≥40 years, diagnosis of COPD with symptoms for at
             least 2 years

          -  FEV1 ≤50% of predicted normal value, pre-bronchodilator, FEV1/VC &lt;70%

          -  Pre-bronchodilator

        Exclusion Criteria:

          -  Current respiratory tract disorder other than COPD

          -  History of asthma or rhinitis

          -  Significant or unstable cardiovascular disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Andersson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martyn R Partridge, MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Imperial College, NHLI at Charing Cross Hospital, LONDON, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monte Grande</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autonoma de Bs. As.</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daw Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jambes</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malmedy</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montigny-le-tilleul</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Brasil</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Juiz de Fora</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Recife</city>
        <state>PE</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florianopolis</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobenhavn Nv</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rodovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Noida</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dartford</city>
        <state>Kent</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Lanarkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Motherwell</city>
        <state>Lanarkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cookstown</city>
        <state>N. Ireland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Limavady</city>
        <state>Northern Ireland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newtownabbey</city>
        <state>Northern Ireland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barry</city>
        <state>South Glamorgan</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barry</city>
        <state>Vale of Glamorgan</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bradford-on-avon</city>
        <state>Wiltshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Airdrie</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blantyre</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bolton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carrickfergus</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chesterfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>India</country>
    <country>Philippines</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2007</study_first_submitted>
  <study_first_submitted_qc>October 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2007</study_first_posted>
  <results_first_submitted>August 4, 2009</results_first_submitted>
  <results_first_submitted_qc>July 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2012</results_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Symbicort</keyword>
  <keyword>Seretide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>706 subjects were enrolled; 264 were not randomised: 190 with eligibility not fulfilled, 11 with adverse events, 4 with discontinuation criteria, 40 voluntary discontinuations, 2 lost to follow-ups, 6 non-compliance, 1 for safety reasons, 10 with other reasons not specified. 442 subjects were randomised</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Symbicort Turbuhaler First, Then Seretide Diskus</title>
          <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg First, then Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
        </group>
        <group group_id="P2">
          <title>Seretide Diskus First, Then Symbicort Turbuhaler</title>
          <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg First, then Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="217">This was a cross-over study</participants>
                <participants group_id="P2" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Development of study-specific criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Symbicort Turbuhaler First, Then Seretide Diskus</title>
          <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg First, then Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
        </group>
        <group group_id="B2">
          <title>Seretide Diskus First, Then Symbicort Turbuhaler</title>
          <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg First, then Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="217"/>
            <count group_id="B2" value="225"/>
            <count group_id="B3" value="442"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.9" lower_limit="41" upper_limit="82"/>
                    <measurement group_id="B2" value="63.2" lower_limit="40" upper_limit="86"/>
                    <measurement group_id="B3" value="63.1" lower_limit="40" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Expiratory Flow (PEF) 5 Minutes After Morning Dose</title>
        <description>The change from baseline in PEF was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and all days of treatment, with baseline as covariate.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF) 5 Minutes After Morning Dose</title>
          <description>The change from baseline in PEF was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and all days of treatment, with baseline as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="28.5"/>
                    <measurement group_id="O2" value="13.4" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF Before Morning Dose</title>
        <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>PEF Before Morning Dose</title>
          <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>Liters/minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
                <count group_id="O2" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="28.2"/>
                    <measurement group_id="O2" value="7.9" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF 15 Minutes After Morning Dose</title>
        <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>PEF 15 Minutes After Morning Dose</title>
          <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="30.3"/>
                    <measurement group_id="O2" value="16.7" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF Before Evening Dose</title>
        <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>PEF Before Evening Dose</title>
          <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="24.3"/>
                    <measurement group_id="O2" value="1.8" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Before Morning Dose</title>
        <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Before Morning Dose</title>
          <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and contribute sufficient data for the endpoint to be calculated.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0310" spread="0.2460"/>
                    <measurement group_id="O2" value="0.0590" spread="0.2310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 15 Minutes After Morning Dose</title>
        <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 15 Minutes After Morning Dose</title>
          <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and contribute sufficient data for the endpoint to be calculated.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1220" spread="0.2530"/>
                    <measurement group_id="O2" value="0.1030" spread="0.3720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Before Evening Dose</title>
        <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Before Evening Dose</title>
          <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1470" spread="0.2470"/>
                    <measurement group_id="O2" value="0.1060" spread="0.2010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PEF From Before Dose to 5 Minutes After Dose in the Morning</title>
        <description>The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with pre-dose run-in/washout as covariate.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PEF From Before Dose to 5 Minutes After Dose in the Morning</title>
          <description>The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with pre-dose run-in/washout as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0160" spread="0.2"/>
                    <measurement group_id="O2" value="0.0030" spread="0.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PEF From Before Dose to 15 Minutes After Dose in the Morning</title>
        <description>The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with mean pre-dose run-in/washout as covariate.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PEF From Before Dose to 15 Minutes After Dose in the Morning</title>
          <description>The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with mean pre-dose run-in/washout as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="16.2"/>
                    <measurement group_id="O2" value="6.1" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FEV1from Before Dose to 5 Minutes After Dose in the Morning</title>
        <description>The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with mean pre-dose run-in/washout as covariate.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1from Before Dose to 5 Minutes After Dose in the Morning</title>
          <description>The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with mean pre-dose run-in/washout as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="20.8"/>
                    <measurement group_id="O2" value="9.6" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FEV1 From Before Dose to 15 Minutes After Dose in the Morning</title>
        <description>The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with mean pre-dose run-in/washout as covariate.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1 From Before Dose to 15 Minutes After Dose in the Morning</title>
          <description>The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with mean pre-dose run-in/washout as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0930" spread="0.1870"/>
                    <measurement group_id="O2" value="0.0280" spread="0.1630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FEV1 From Before Dose to 5 Minutes After Dose at the Clinic</title>
        <description>The change from pre-dose was calculated using the pre-dose baseline value (run-in and washout period respectively), and pre-dose value at day 1, with pre-dose run-in/washout as covariate.</description>
        <time_frame>Baseline (run-in, and washout) and day 1 of treatment period</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1 From Before Dose to 5 Minutes After Dose at the Clinic</title>
          <description>The change from pre-dose was calculated using the pre-dose baseline value (run-in and washout period respectively), and pre-dose value at day 1, with pre-dose run-in/washout as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1120" spread="0.1950"/>
                    <measurement group_id="O2" value="0.0440" spread="0.1640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forced Vital Capacity (FVC) From Before Dose to5 Minutes After Dose at the Clinic</title>
        <description>The change from pre-dose was calculated using the pre-dose baseline value (run-in and washout period respectively), and pre-dose value at day 1, with pre-dose run-in/washout as covariate.</description>
        <time_frame>Baseline (run-in, and washout) and day 1 of treatment period</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Vital Capacity (FVC) From Before Dose to5 Minutes After Dose at the Clinic</title>
          <description>The change from pre-dose was calculated using the pre-dose baseline value (run-in and washout period respectively), and pre-dose value at day 1, with pre-dose run-in/washout as covariate.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0950" spread="0.1370"/>
                    <measurement group_id="O2" value="0.0490" spread="0.1060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Capacity of Daily Living in the Morning (CDLM) (Change From Pre to End of Treatment)</title>
        <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate. Score scale 0 - 5 with 0=worst and 5 = best.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus First</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Capacity of Daily Living in the Morning (CDLM) (Change From Pre to End of Treatment)</title>
          <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate. Score scale 0 - 5 with 0=worst and 5 = best.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1920" spread="0.2530"/>
                    <measurement group_id="O2" value="0.1240" spread="0.2310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difficulty in Getting Out From Bed (MASQ) (Change From Pre to End of Treatment)</title>
        <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate. Score scale 0 - 5 with 0=worst and 5 = best.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Difficulty in Getting Out From Bed (MASQ) (Change From Pre to End of Treatment)</title>
          <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate. Score scale 0 - 5 with 0=worst and 5 = best.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.64"/>
                    <measurement group_id="O2" value="0.14" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Clinical Chronic Obstructive Pulmonary Disease (COPD) Questionnaire (Change From Pre to End of Treatment)</title>
        <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate. Score scale 0 - 6 with 0=worst and 6 = best.</description>
        <time_frame>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</time_frame>
        <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
          </group>
          <group group_id="O2">
            <title>Seretide Diskus</title>
            <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
          </group>
        </group_list>
        <measure>
          <title>The Clinical Chronic Obstructive Pulmonary Disease (COPD) Questionnaire (Change From Pre to End of Treatment)</title>
          <description>The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate. Score scale 0 - 6 with 0=worst and 6 = best.</description>
          <population>Includes all subjects with at least one dose of study medication and who contribute sufficient data for the endpoint to be calculated.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.75"/>
                    <measurement group_id="O2" value="0.19" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Symbicort Turbuhaler</title>
          <description>Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg</description>
        </group>
        <group group_id="E2">
          <title>Seretide Diskus</title>
          <description>Seretide Diskus (salmeterol/fluticasone) 50/500 μg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive oulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to any publication or disclosure, the PI provides AstraZeneca with preliminary data and drafts and with the proposed final manuscript. AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript to review it and may within such time frame require that submission for publication or disclosure be delayed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>AZTrial_Results_Posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

